Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy.

Piroth L, Carrat F, Larrat S, Goderel I, Martha B, Payan C, Lunel-Fabiani F, Bani-Sadr F, Perronne C, Cacoub P, Pol S, Morand P.

J Hepatol. 2008 Dec;49(6):892-8. doi: 10.1016/j.jhep.2008.06.024.

PMID:
18752863
2.

Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.

Hofer H, Aydin I, Neumueller-Guber S, Mueller C, Scherzer TM, Staufer K, Steindl-Munda P, Wrba F, Ferenci P.

J Viral Hepat. 2011 Jul;18(7):513-7. doi: 10.1111/j.1365-2893.2010.01340.x.

PMID:
20565572
3.

SEN Virus infection in HIV/HCV coinfected patients.

Sagir A, Adams O, Oette M, Vogel M, Kupfer B, Emmelkamp J, Rockstroh J, Häussinger D.

Eur J Med Res. 2008 Nov 24;13(11):495-9.

PMID:
19073384
4.

Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.

Khattab E, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo C, Zoulim F.

J Clin Virol. 2005 Jun;33(2):150-7.

PMID:
15911431
5.

Prevalence and clinical significance of SEN-H virus in chronic hepatitis B, C and delta infections in Turkey.

Cakaloğlu Y, Akyüz F, Bozaci M, Ibrişim D, Pinarbaşi B, Demir K, Kaymakoğlu S, Beşişik F, Badur S, Okten A.

Turk J Gastroenterol. 2008 Jun;19(2):104-8.

6.

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.

Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein C; Hep-Net B/C Co-infection Study Group..

J Hepatol. 2008 Nov;49(5):688-94. doi: 10.1016/j.jhep.2008.03.028.

PMID:
18490077
7.

[Viral co-infections in hepatitis C: HBV, HBV-C/HGV and TTV studies].

Pár A, Takács M, Brojnás J, Berencsi G, Paál M, Horányi M, Miseta A, Hegedüs G, Mózsik G, Hunyady B.

Orv Hetil. 2004 May 9;145(19):987-92. Hungarian.

PMID:
15181733
8.

GB virus C (GBV-C) infection in patients with chronic hepatitis C. Influence on liver disease and on hepatitis virus behaviour: effect of interferon alfa therapy.

Pawlotsky JM, Roudot-Thoraval F, Muerhoff AS, Pellerin M, Germanidis G, Desai SM, Bastie A, Darthuy F, Rémiré J, Zafrani ES, Soussy CJ, Mushahwar IK, Dhumeaux D.

J Med Virol. 1998 Jan;54(1):26-37.

PMID:
9443106
9.

Characterization of GBV-C infection in HIV-1 infected patients.

Canducci F, Uberti Foppa C, Boeri E, Racca S, Gallotta G, Grasso MA, Calori G, Lazzarin A, Clementi M.

J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):191-4.

PMID:
14518722
10.

Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.

Sheng WH, Hung CC, Wu RJ, Wang JT, Chen PJ, Chang SC, Kao JH.

Clin Infect Dis. 2007 Feb 15;44(4):584-90.

11.

Frequency and genotype of GB virus C among Iranian patients infected with HIV.

Hekmat S, Mohraz M, Vahabpour R, Jam S, Bahramali G, Banifazl M, Aghakhani A, Eslamifar A, Mahboudi F, Edalat R, Ramezani A.

J Med Virol. 2008 Nov;80(11):1941-6. doi: 10.1002/jmv.21314.

PMID:
18814233
12.

Management of HIV and hepatitis virus coinfection.

Mendes-Corrêa M, Núñez M.

Expert Opin Pharmacother. 2010 Oct;11(15):2497-516. doi: 10.1517/14656566.2010.500615. Review.

PMID:
20629586
13.

Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.

Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL.

J Gastroenterol Hepatol. 2010 Feb;25(2):259-63. doi: 10.1111/j.1440-1746.2009.06006.x.

PMID:
19817959
14.

Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.

Ladep NG, Agaba PA, Agbaji O, Muazu A, Ugoagwu P, Imade G, Cooke G, McCormack S, Taylor-Robinson SD, Idoko J, Kanki P.

World J Gastroenterol. 2013 Mar 14;19(10):1602-10. doi: 10.3748/wjg.v19.i10.1602.

15.

[Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].

Liu B, Cai WP, Hu FY, Xu M, Lan Y, Tang XP.

Zhonghua Gan Zang Bing Za Zhi. 2013 Nov;21(11):829-33. doi: 10.3760/cma.j.issn.1007-3418.2013.11.008. Chinese.

PMID:
24331692
16.

GB virus C/hepatitis G virus infection in chronic hepatitis C patients with and without interferon-alpha therapy.

Yu ML, Chuang WL, Dai CY, Chen SC, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chang WY.

Antiviral Res. 2001 Dec;52(3):241-9.

PMID:
11675141
17.

Response to interferon of GB virus C and hepatitis C virus in patients with chronic hepatitis.

Inoue T, Sakamoto M, Akahane Y, Okamoto H, Miyakawa Y, Mayumi M.

Am J Gastroenterol. 1997 Nov;92(11):1981-5.

PMID:
9362176
18.

[Impact of HIV on HCV, GBV-C/HGV, and HBV infection].

Hayashi K, Toyoda H, Nakano I, Fukuda Y, Takamatsu J.

Nihon Rinsho. 2002 Apr;60(4):798-802. Review. Japanese.

PMID:
11968791
19.

SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration.

Sagir A, Adams O, Kirschberg O, Erhardt A, Heintges T, Haussinger D.

World J Gastroenterol. 2004 Jul 1;10(13):1893-7.

20.

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.

Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V, Craxì A, Cacciola I, Squadrito G, Raimondo G.

J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):172-5.

PMID:
14518718
Items per page

Supplemental Content

Support Center